Others titles

  • NGC Guideline Summaries
  • Evidence-based Clinical Practice Guidelines
  • Guidline Summaries by Clinical Speciality
  • Guidline Summaries by Category
  • Guidline Summaries by Intended Users

Keywords

  • Clinical Guidelines
  • Practice Guidelines
  • Guideline Attributes
  • Inclusion Criteria
  • Guideline Summary
  • MESH Terminology

Clinical Practice Guideline Summaries

This dataset contains summaries of evidence-based clinical practice guidelines. Clinical practice guidelines are statements that include recommendations intended to optimize patient care that is informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options. See also the similar dataset Nursing Order Sets Data Package.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Standard End User License Agreement (“EULA”) applies to customers of John Snow Labs Inc. (as defined below), using any product of John Snow Labs Inc. on John Snow Labs Marketplace as defined below (hereinafter referred to “you”) and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading, installing, and/or using (as applicable) any Product of John Snow Labs (as defined below), you automatically agree to be bound by, and use our Products in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE PURCHASING, INSTALLING OR USING OUR PRODUCTS MADE AVAILABLE ON JOHN SNOW LABS MARKETPLACE.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of our Products after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“John Snow Labs Data Library” means a data library located at https://www.johnsnowlabs.com;

“Products” means products and services of John Snow Labs that you download and use from listings in John Snow Labs Data Library;

Important Notice

By installing and using our Products, you acknowledge that the use of the Products can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use the Products for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Products can be used by an individual, business or other legal entity, or both. If you are entering into this EULA, or using the Products, on behalf of a company or other legal entity, you represent that you have the authority to bind such entity to this EULA, in which case “you” shall refer to such entity.

In the event you have entered into a separate written agreement with John Snow Labs regarding the Products that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all.

Your Access and Use

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, license to install, access to, modify, and use of, the Products worldwide (subject to applicable export laws) during the term of this EULA (as described below) solely for research, private study and personal use of Products.

This license is personal to you, and you may not resell our Products, permit other users access to our Products through your account. Your right to use our Products is limited by all terms and conditions set forth in this EULA.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Products, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Products are protected by applicable intellectual property laws, including United States copyright law and international treaties.

Except for the foregoing license, you have no other rights in the Products and you may not modify, edit, copy, reproduce, create derivative works of, reverse engineer, alter, enhance or in any way exploit the Products in any manner. If you breach any of this EULA, the above license will terminate automatically.

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of the Products. You are responsible for end users’ use of your content and the Products. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and the Products by such end user. We do not provide any support or services to end users unless we have a separate agreement with you or an end user obligating us to provide such support or services.

Restrictions

You will access or use our Products solely via John Snow Labs Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. reproduce, modify, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of any of our Products or its technological features or measures;
  2. rent, lease, sell, resell, loan, distribute, or sublicense access to any of our Products;
  3. circumvent or disable any security or technological features or measures of our Products;
  4. use our intellectual property rights without our express prior written authorization;
  5. use our Products for more than one trial period, unless the trial period is extended by John Snow Labs’ prior written permit;
  6. use our Products with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of the Products;
  7. store, copy, modify, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on our Products (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  8. use any automated tool (e.g., robots, spiders) to access or use our Products, or to store, copy, modify, distribute, or resell any Content;
  9. circumvent or disable any rights management, usage rules, or other security features of our Products;
  10. use our Products in a manner that overburdens, or that threatens the integrity, performance, or availability of, our Products; or
  11. remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Fees and Taxes

Your use of the Products is subject to our fees. All fees are given on our website https://www.johnsnowlabs.com. Except as set forth in this EULA, the fees are non-refundable. We are entitled to revise our fees from time to time.

The fees exclude any federal, state or local taxes, VAT, GST, or similar taxes. You are responsible for identification and payment of all taxes as required by applicable law.

Term and Termination

This EULA will become effective as of the date of your order of Products and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use our Products, if you or your end user’s use of the Products:

  1. is in breach of this EULA;
  2. poses a security risk to our Products;
  3. could adversely impact our systems, the Products or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use our Products, if you fail to perform your payment obligations, or you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

We may also suspend or terminate your right to use our Products without any reason upon a relevant 30 days’ written notice to you and will refund the unused fees pre-paid by you for access to the Products for the affected time period (if any). Where your access is suspended or terminated by the breach of this EULA or applicable laws, John Snow Labs will will not provide, or be liable for, any refund.

You will cease use of the Products during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Support

If applicable to your Product, John Snow Labs will provide you with the support services. If you use a trial access, support services are excluded. Under this EULA, our support services exclude any installation, training, maintenance services (including any error corrections, bug fixes, or new releases), technical assistance, consulting services, or other services of any kind. Such services are provided at John Snow Labs’ discretion.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Access to our Products

We do not provide you with the equipment to access our Products. You are responsible for all fees charged by third parties related to your access and use of our Products (e.g., charges by Internet service providers).

You are responsible for monitoring your use of the Products, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of the Products for auditing purposes.

You also certify that you are legally permitted to use the Products, and take full responsibility for the selection and use of the Products. This EULA is void where prohibited by law, and the right to use the Products is revoked in such jurisdictions. John Snow Labs makes no claim that the Products may be lawfully used outside of the United States. If you use the Products from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Our Products may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using our Products (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using our Products, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

The Products, including software, is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to the Products or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on our Products are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of our Products, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs and may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in our Products are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF THE PRODUCTS IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of the Products; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of the Products will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Products. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about our Products or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

National Guideline Clearinghouse (NGC) provides structured summaries containing information from clinical practice guidelines. NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ),U.S. Department of Health and Human Services.

NGC supports AHRQ’s mission to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable by providing objective, detailed information on clinical practice guidelines, and to further their dissemination, implementation, and use in order to inform health care decisions.

NGC uses a systematic approach to decide when it is appropriate to include author, year citations in the Major Recommendations field and full citations in the References Supporting the Recommendations field. Two criteria drive the decision-making process: (1) the recommendations are explicitly stated, and (2) those explicit statements are referenced. The first criterion means that the recommendations in the guideline document are easily identified, stand-alone and action-oriented statements. Explicit recommendation statements are not interspersed among rationale in the guideline document. The rationale for the recommendations may be provided in sections before or after the actual recommendations but not within the same body of content as the recommendations. The second criterion means that the reference(s) supporting the explicit recommendation is (are) provided at the end of the statement. References cited in the rationale for the recommendation are not captured.

NGC’s master’s level indexers apply terms from selected UMLS vocabularies to each guideline summary to facilitate searching and browsing and to create relationships between similar documents. These vocabularies are:
-Healthcare Common Procedure Coding System (HCPCS)
-International Classification of Diseases – Clinical Modification (ICD-9-CM)
-Medical Subject Headings (MeSH)
-Physician Data Query (PDQ)
-Standard Product Nomenclature (SPN)
-Systemized Nomenclature of Medicine (Clinical Terms) (SNOMED CT)
-UMLS Metathesaurus (MTH)
-Universal Medical Device Nomenclature System (UMDNS)

As part of the NGC Annual Verification, many guidelines are withdrawn from the Web site at the end of every year because they no longer meet the Inclusion Criteria with respect to date. NGC’s inclusion criteria specifically require that guidelines represented in their database have been developed, reviewed, or revised within the last five years. All guidelines that no longer meet this criterion are removed from the Web site at the end of each calendar year.

About this Dataset

Data Info

Date Created

1997

Last Modified

2018-07-02

Version

2018-07-02

Update Frequency

Never

Temporal Coverage

N/A

Spatial Coverage

N/A

Source

John Snow Labs; National Guideline Clearinghouse (NGC);

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

Clinical Guidelines, Practice Guidelines, Guideline Attributes, Inclusion Criteria, Guideline Summary, MESH Terminology

Other Titles

NGC Guideline Summaries, Evidence-based Clinical Practice Guidelines, Guidline Summaries by Clinical Speciality, Guidline Summaries by Category, Guidline Summaries by Intended Users

Data Fields

Name Description Type Constraints
Guideline_IDThe Guideline unique identifierintegerrequired : 1level : Nominal
Guideline_TitleIdentifies the complete title of the guideline.stringrequired : 1
Bibliographic_SourcesIdentifies the complete bibliographic source(s) for the published guideline as disseminated by the guideline developer(s). The number of references cited is included for each source.string-
Guideline_StatusIdentifies the current status of the summary including whether the guideline is an updated version of a previously issued document, whether an update is in progress, and whether the guideline meets the 2013 (revised) inclusion criteria.string-
Regulatory_AlertIdentifies important warnings and/or revised regulatory information released by the U.S. Food and Drug Administration (FDA) or other official regulatory body for a drug and/or device for which recommendations are provided in the original guideline document.string-
Scope_Disease_ConditionsIdentifies the major areas of clinical medicine or health care addressed in the guideline. Values are expressed using the natural language expressions found in the text of the guideline.string-
Scope_Other_Disease_ConditionsIndicates the presence of multiple chronic conditions by listing co-existing or comorbid chronic diseases or conditions for which specific recommendations are provided.string-
Scope_Guideline_CategoryClassifies the major focus of the guideline. Values are selected from the appropriate concepts in the Classification Scheme.string-
Scope_Clinical_SpecialityClassifies the clinical specialties that might use the guideline professionally. Values are selected from the appropriate concepts in the Classification Scheme.string-
Scope_Intended_UsersClassifies the groups intended to use the guideline. Values are selected from the appropriate concepts in the Classification Scheme.string-
Scope_Guideline_ObjectivesDescribes the objectives of the guideline as specified in the original guideline document.string-
Scope_Target_PopulationDescribes the target population(s) addressed in the guideline.string-
Scope_Interventions_and_Practices_ConsideredIdentifies the specific clinical interventions and practices considered in the guideline. Values are expressed using natural language expressions found in the text of the guideline.string-
Scope_Major_Outcomes_ConsideredDescribes the most important specific outcomes or performance measures considered in the guideline. Includes patient outcomes described in treatment guidelines and diagnostic test performance characteristics described in diagnosis or screening guidelines.string-
Methodology_EvidenceClassifies the methods used to collect and select the evidence that were evaluated. Values are selected from the appropriate concepts in the Classification Scheme.string-
Methodology_Description_EvidenceDescribes/summarizes the specific methods used to collect and select the evidence, as identified in the text of the guideline or by the guideline developer. Can include detailed search strategies, lists of journals scanned, keywords, database sources, inclusion and exclusion criteria, etc.string-
Methodology_Number_of_DocumentsIdentifies the number of source documents that were identified by the methods described above under "Methodology_Description_Evidence".string-
Methodology_Quality_and_Strength_EvidenceClassifies the methods used by the guideline developer to determine what relative importance to give the evidence they obtained. Values are selected from the appropriate concepts in the Classification Scheme.string-
Methodology_Rating_Scheme_EvidencePresents the rating scheme for strength of evidence, when given.string-
Methodology_AnalysisClassifies the methods used by the guideline developer to evaluate the data in the evidence they obtained. Values are selected from the appropriate concepts in the Classification Scheme.string-
Methodology_Description_AnalysisDescribes the methods used to analyze the evidence. Presents additional definition for the values presented under "Methodology_Analysis" (for example, defines "systematic" or summarizes the details of the meta-analyses).string-
Methodology_RecommendationsIdentifies the methods used to translate evidence into statements that will assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Values are selected from the appropriate concepts in the Classification Scheme.string-
Methodology_Description_RecommendationsCaptures the details of the methods used to translate evidence into recommendation statements. Issues considered by the guideline developers during recommendation formulation such as cost, patient preference, and values, are also captured.string-
Methodology_Rating_Scheme_RecommendationsCaptures the weighted scheme used by the guideline developer to determine what relative strength or importance to give to the recommendations being made.string-
Methodology_Cost_AnalysisDescribes any formal cost analysis performed and any published cost analyses reviewed.string-
Methodology_Guideline_ValidationLists the method(s) used to validate the recommendations of the guideline.string-
Methodology_Description_Guideline_ValidationCaptures the details of the method(s) used by the guideline developer to validate the guideline.string-
Recommendations_MajorIdentifies the major recommendations of the guideline.string-
Recommendations_Clinical_AlgorithmsIdentifies the recommendations expressed in the form of clinical algorithm(s) and where the algorithm(s) are providedstring-
Supporting_Recommendations_ReferencesLists the references of evidence supporting the recommendations when applicable. This field opens in a new window and PubMed links are provided when available.string-
Supporting_Recommendations_Evidence_TypeDescribes the type of evidence supporting the recommendations.string-
Implementing_Recommendations_Potential_BenefitsDescribes the anticipated benefits associated with implementing the guideline's recommendations. When applicable, the field also includes information on the major subgroup(s) of patients within the target population most likely to benefit from the guideline recommendations.string-
Implementing_Recommendations_Potential_HarmsDescription of the anticipated harms, potential risks or adverse consequences associated with the guideline's recommendations, as stated in the guideline text, to target populations or intended users.string-
ContraindicationsIdentifies the instances (e.g., co-morbidities) that might render the use of medications or procedures improper, undesirable, or inadvisable.string-
Qualifying_StatementsPresents qualifying statements or important caveats pertaining to the major recommendations of the guideline. Identifies areas of uncertainty and presents a brief description of how the guideline developer addressed this uncertainty in developing the recommendations.string-
Guidelines_Implementation_StrategyDescribes specific strategies, aims, performance measures, or plans for implementing the guideline recommendations.string-
Guidelines_Implementation_ToolsIdentifies the types of implementation tools provided by the guideline developer to facilitate the implementation of the guideline. Values are selected from the appropriate concepts in the Classification Schemestring-
Guidelines_Implementation_NQMC_MeasuresIdentifies link(s) to related quality measures in the National Quality Measures Clearinghouse™ (NQMC).string-
IOM_Care_NeedClassifies the guideline into one of four Institute of Medicine (IOM) care need classifications: End of life care; Getting better; Living with illness; Staying healthy.string-
IOM_DomainClassifies the guideline into one or more of the four Institute of Medicine (IOM) care domains: Effectiveness; Patient-centeredness; Safety; Timeliness.string-
Information_AdaptationIdentifies that the guideline has been adapted from another guideline and identifies the source document.string-
Information_Date_ReleasedIdentifies the date the guideline was released to the public.string-
Information_Guideline_DevelopersIdentifies the organization(s) responsible for the development of the guideline.string-
Information_Guideline_Developers_CommentIf the guideline developer is a consortium or represents a group of organizations, this field identifies the individual organizations by name.string-
Information_Source_FundingIdentifies source(s) of financial support for guideline development, as identified in the guideline text or by the guideline developer. Lists any gran numbers associated with funding, as identified in the guideline text or by the guideline developer.string-
Information_Guideline_CommitteeIdentifies formal name, if any, of committee/subcommittee within the guideline developer organization(s) responsible for developing the guideline.string-
Information_Guideline_Author_GroupDescribes the composition of the group/committee that authored the guideline, including professional degrees and affiliations, and lists the names of individual committee members, where given.string-
Information_Conflicts_of_InterestCaptures relationships between individuals of the guideline development committee/group and for-profit and not-for-profit companies or organizations that could potentially influence that individual's contribution to the guideline's development.string-
Information_EndorsersIdentifies organization(s) that have endorsed the guideline. Each organization is classified by the major designation or function (derived from the Organization Type attribute), such as "Medical Specialty Society" or "Professional Association."string-
Information_Guideline_AvailabilityIdentifies information about the availability of the guideline. Provides links to the full-text document and ordering information for print copies.string-
Information_Companion_Document_AvailabilityIdentifies the companion documents produced by the guideline developer that are considered relevant to the guideline.string-
Information_Patient_ResourcesIdentifies patient resources that are directly related (i.e., derived and/or prepared from the guideline by the guideline developer) to the guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.string-
Information_NGC_StatusIdentifies when the guideline was completed or revised by ECRI Institute, and verified by the developing organization(s).string-
Information_Copyright_StatementProvides the copyright statement of the organization that submitted the guideline.string-
NGC_DisclaimerProvides disclaimer information about the relationship between NGC (including its sponsor, the Agency for Healthcare Research and Quality (AHRQ), and its contractor, ECRI Institute) and the guidelines and guideline developers represented on the Web site.string-

Data Preview

No data for preview